Estrella Biopharma, a preclinical-stage biopharmaceutical company focusing on cancer therapeutics, went public via a SPAC merger with TradeUP Acquisition, a publicly traded special purpose acquisition company, in a $399m deal. "We are pleased to close this transaction and are committed to the continued advancement of our clinical programs. Our anti-CD19 ARTEMIS T-cell therapy has the potential to improve patient outcomes while reducing the risk of Cytokine Release Syndrome. This marks a critical advancement in the management of blood cancer treatments," Liu, Estrella President and CEO.